Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue, Suite 240
Henderson, NV 89052
tel: (702) 835-6300
fax: (702) 260-7405
company website
11500 South Eastern Avenue, Suite 240
Henderson, NV 89052
tel: (702) 835-6300
fax: (702) 260-7405
company website
Spectrum Pharmaceuticals, Inc.
REDEFINING CANCER CARE
REDEFINING CANCER CARE
Spectrum Pharmaceuticals, Inc., is a rapidly growing small biotechnology company headquartered in Henderson, Nevada. The company is fully integrated with expertise both in drug development and commercialization.
Dedicated to Oncology
For more than a decade, Spectrum Pharmaceuticals has been dedicated to advancing oncology treatments with passion and commitment. Through its commercial, research, and business development activities, Spectrum strives to make a lasting impact on bettering the treatment of cancer.
More than 17,000 patients and their families have been impacted and treated with Spectrum’s products. Spectrum is embarking upon the most important growth opportunity in Spectrum’s history. The endeavors and goals are important to the company, but they mean even more to thousands of cancer patients, employees and shareholders.
Business Development
The year 2014 was important for the company. Spectrum was able to secure two partners to market drugs in important regions, such as greater China and India. In September, Spectrum granted CASI Pharmaceuticals, Inc. (NASDAQ: CASI) the exclusive rights for greater China to distribute three of Spectrum’s drugs, two of which are already commercialized in the United States—ZEVALIN® and MARQIBO®—and EVOMELA®, which is under FDA review. In December, Spectrum out-licensed ZEVALIN rights for India to Dr. Reddy’s Laboratories, Ltd. Spectrum continues to look for opportunities to add to its strong pipeline and product portfolio as well as for partners to better develop Spectrum’s current assets.
Advancing a Pipeline for Cancer Patients
The year 2015 should be pivotal for several drugs in Spectrum’s pipeline. Spectrum has made tremendous progress in the development of SPI-2012, a long-acting white blood cell–stimulating drug. In February 2015, Spectrum licensed Poziotinib, a pan-HER inhibitor in Phase 2 clinical trials from Hanmi Pharmaceutical Co., Ltd. Spectrum is especially excited about the prospects of this drug in breast cancer, where the early clinical data is very strong. EVOMELA is a propylene glycol-free formulation of melphalan with improved stability compared to the approved versions of melphalan. Apaziquone is a late-stage bladder cancer drug with promising clinical data and acceptable safety that could satisfy significant unmet medical needs.
Spectrum is grateful for your continued support in achieving these goals of bringing important drugs to cancer patients.